Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia

被引:41
|
作者
Koziel, H
Kim, S
Reardon, C
Li, XH
Garland, R
Pinkston, P
Kornfeld, H
机构
[1] Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Univ, Sch Med, Boston, MA 02118 USA
[4] Boston Med Ctr, Div Pulm & Crit Care, Boston, MA USA
关键词
D O I
10.1164/ajrccm.160.6.9902099
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The relationship of serum human immunodeficiency virus-1 (HIV-1) RNA levels to HIV-1 RNA levels in other compartments, such as the lungs, is not well characterized. The purpose of this study was to determine the viral burden of HIV-1 in the lungs by comparing HIV-1 RNA in cell-free bronchoalveolar lavage fluid (BALF) with that in serum. Specimens were examined from 77 HIV-seropositive adults (CD4(+) cell counts: 0 to 700 cells/mm(3); 48% receiving prescribed antiretroviral agents), comprising 43 asymptomatic individuals who were compared with 34 persons with active lung disease caused by Pneumocystis carinii (n = 26), bacteria (n = 3), Mycobacterium avium complex (n = 2), Nocardia sp. (n = 1), Aspergillus sp. (n = 1), or pulmonary Kaposi's sarcoma (n = 1). For serum HIV-1 RNA, the proportion of subjects with detectable levels and the mean values were similar for asymptomatic individuals and persons with active lung disease (85% versus 86%, respectively) (6.64 x 10(4) versus 1.81 x 10(5) HIV-1 RNA copies/ml; p = 0.13). In contrast, HIV-1 RNA in BALF was more often detected (16% versus 62%; p = 0.001), and mean values were higher(1.04 x 10(5) versus 3.31 x 10(6) HIV-1 RNA copies/ml; p = 0.032), in subjects with active lung disease than in asymptomatic subjects, independent of early or advanced clinical stages of HIV-related disease. For both study groups, HIV-l RNA levels in BALF exceeded those in serum in 56% of cases by up to 66-fold, and did not correlate with local levels of tumor necrosis factor-alpha granulocyte-macrophage colony-stimulating factor, or interleukin-16. HIV-1 proviral DNA in cells from BALF was detected in up to 86% of subjects, more frequently in persons with advanced HIV disease (p = 0.0496), and often involved > 10% of BALF cells, but did not correlate with HIV-1 RNA detected in BALF. These data provide evidence for active HIV-1 replication in the lungs. HIV-1 replication is compartmentalized relative to serum, may be restricted, is independent of HIV-1 proviral DNA and clinical stage of HIV, and may be influenced by pulmonary disease such as P. carinii pneumonia or by other local or lung-specific factors. The lungs represent a large reservoir for HIV-1, and may present a source of persistent HIV-1 replication even during periods of apparent clinical latency of HIV-1 infection.
引用
收藏
页码:2048 / 2055
页数:8
相关论文
共 50 条
  • [1] PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PATIENTS
    GLATT, AE
    CHIRGWIN, K
    ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (02) : 271 - 279
  • [2] Simultaneous Pneumocystis carinii and pneumococcal pneumonia in human immunodeficiency virus-infected children
    Glatman-Freedman, A
    Ewig, JM
    Dobroszycki, J
    Mitsudo, S
    Glaser, JH
    JOURNAL OF PEDIATRICS, 1998, 132 (01): : 169 - 171
  • [3] PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED INFANTS AND CHILDREN
    GOODWIN, SD
    PHARMACOTHERAPY, 1993, 13 (06): : 640 - 646
  • [4] PREVENTING PNEUMOCYSTIS-CARINII PNEUMONIA IN PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    SIMONDS, RJ
    HUGHES, WT
    FEINBERG, J
    NAVIN, TR
    CLINICAL INFECTIOUS DISEASES, 1995, 21 : S44 - S48
  • [5] PREDICTING RISK OF PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
    RUTSTEIN, RM
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1991, 145 (08): : 922 - 924
  • [6] DAPSONE PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED CHILDREN
    CRUCIANI, M
    CONCIA, E
    GATTI, G
    FIOREDDA, F
    BASSETTI, D
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (01) : 80 - 81
  • [7] PNEUMOCYSTIS-CARINII PNEUMONIA IN CHILDREN INFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    MOSS, WJ
    DONAHUE, C
    ABRAMS, E
    PEDIATRIC AIDS AND HIV INFECTION-FETUS TO ADOLESCENT, 1994, 5 (02): : 108 - 111
  • [8] Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus
    Zar, HJ
    Dechaboon, A
    Hanslo, D
    Spolles, P
    Magnus, KG
    Hussey, G
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (07) : 603 - 607
  • [9] RECOMMENDATIONS FOR PROPHYLAXIS AGAINST PNEUMOCYSTIS-CARINII PNEUMONIA FOR PERSONS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    MASUR, H
    FEINBERG, J
    BOZZETTE, SA
    DEGRUTTOLA, V
    EDLIN, B
    EISINGER, R
    ELSADR, W
    ELLENBERG, S
    FEIGAL, D
    FRAME, P
    GOLDBERGER, M
    HAFNER, R
    HARDY, WD
    HARRINGTON, M
    HUGHES, W
    KERKERING, T
    KOVACS, J
    LEOUNG, G
    MONTANER, J
    MUNOZ, A
    PHAIR, J
    SATTLER, F
    SPECTOR, S
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1993, 6 (01): : 46 - 55
  • [10] Pneumocystis carinii pneumonia without the human immunodeficiency virus.
    Ly, H
    Decker, M
    Sherman, SE
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2003, 18 : 71 - 71